Glucocorticoid receptor blockade as disease-modifying treatment for depression with childhood trauma: a study protocol of the RESET-medication study

被引：0
|
作者：
Linsen, F. [1 ]
Verhoeven, J. [1 ]
Bet, P. [1 ]
Penninx, B. [1 ]
Meijer, O. [2 ]
Vinkers, C. [1 ]
机构：
[1] Amsterdam UMC Locat VUmc, Dept Psychiat, Amsterdam, Netherlands
[2] Leiden UMC, Dept Med, Div Endocrinol, Leiden, Netherlands
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2021年 / 53卷
关键词：
D O I：
10.1016/j.euroneuro.2021.10.772
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.0700
引用
收藏
页码：S513 / S513
页数：1
相关论文
共 50 条
  • [21] Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study
    Cameron, Elaine
    Rog, David
    McDonnell, Gavin
    Overell, James
    Pearson, Owen
    French, David P.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 27 : 378 - 382
  • [22] Disease Remission State in Patients Treated With the Combination of Tumor Necrosis Factor Blockade and Methotrexate or With Disease-Modifying Antirheumatic Drugs A Clinical and Imaging Comparative Study
    Saleem, Benazir
    Brown, Andrew K.
    Keen, Helen
    Nizam, Sharmin
    Freeston, Jane
    Karim, Zunaid
    Quinn, Mark
    Wakefield, Richard
    Hensor, Elizabeth
    Conaghan, Philip G.
    Emery, Paul
    ARTHRITIS AND RHEUMATISM, 2009, 60 (07): : 1915 - 1922
  • [23] Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
    Fernandez, Oscar
    Duran, Eduardo
    Ayuso, Teresa
    Hernandez, Luis
    Bonaventura, Inmaculada
    Forner, Mireia
    PLOS ONE, 2017, 12 (10):
  • [24] Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study
    Lorscheider, J.
    Kuhle, J.
    Izquierdo, G.
    Lugaresi, A.
    Havrdova, E.
    Horakova, D.
    Hupperts, R.
    Duquette, P.
    Girard, M.
    Prat, A.
    Grand'Maison, F.
    Grammond, P.
    Sola, P.
    Ferraro, D.
    Trojano, M.
    Ramo-Tello, C.
    Lechner-Scott, J.
    Pucci, E.
    Solaro, C.
    Slee, M.
    Van Pesch, V.
    Sanchez Menoyo, J. L.
    van der Walt, A.
    Butzkueven, H.
    Kappos, L.
    Kalincik, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (02) : 363 - 370
  • [25] Sodium selenate as a disease-modifying treatment for mild-moderate Alzheimer's disease: an open-label extension study
    Vivash, Lucy
    Malpas, Charles B.
    Hovens, Christopher M.
    Brodtmann, Amy
    Collins, Steven
    Macfarlane, Stephen
    Velakoulis, Dennis
    O'Brien, Terence J.
    BMJ NEUROLOGY OPEN, 2021, 3 (02)
  • [26] A Simulation Study on the Estimation of the Effect in the Hypothetical Scenario of No Use of Symptomatic Treatment in Trials for Disease-Modifying Agents for Alzheimer's Disease
    Lasch, Florian
    Guizzaro, Lorenzo
    Petavy, Frank
    Gallo, Ciro
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (02): : 386 - 399
  • [27] A Real-World Study of Disease-Modifying Drug Treatment Patterns in US Patients with Multiple Sclerosis Newly Initiating Treatment
    Nicholas, Jacqueline
    Edwards, Natalie C.
    Harlow, Danielle
    Phillips, Amy
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 20 - 20
  • [28] Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study
    Payne, Thomas
    Sassani, Matilde
    Buckley, Ellen
    Moll, Sarah
    Anton, Adriana
    Appleby, Matthew
    Maru, Seema
    Taylor, Rosie
    McNeill, Alisdair
    Hoggard, N.
    Mazza, Claudia
    Wilkinson, Iain D.
    Jenkins, Thomas
    Foltynie, Thomas
    Bandmann, O.
    BMJ OPEN, 2020, 10 (08):
  • [29] A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia
    Vivash, Lucy
    Malpas, Charles B.
    Churilov, Leonid
    Walterfang, Mark
    Brodtmann, Amy
    Piguet, Olivier
    Ahmed, Rebekah M.
    Bush, Ashley, I
    Hovens, Christopher M.
    Kalincik, T.
    Darby, David
    Velakoulis, Dennis
    O'Brien, Terence J.
    BMJ OPEN, 2020, 10 (11):
  • [30] Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study
    N. Giedraitiene
    V. Taluntiene
    G. Kaubrys
    Scientific Reports, 12
12345